newsfilter
← Latest News
GlobeNewswire·

Opiant Pharmaceuticals Announces Additional $2.2 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program

SANTA MONICA, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT) today announced a modification to its contract with the Biomedical Advanced Research and Development Authority ("BARDA") for an additional